18 November 2020 - - US-based biotechnology company Triplet Therapeutics, Inc has appointed Kathy Biberstein, J.D., and Stephen Webster to its board of directors, the company said.

Biberstein brings extensive legal, policy and operations expertise in the global biopharma industry, most recently serving as executive vice president, chief administrative and legal officer, chief compliance and risk officer and board secretary at Alkermes (NASDAQ: ALKS).

Webster brings deep experience in capital markets and financial management, most recently serving as chief financial officer at Spark Therapeutics.

Biberstein and Webster join existing board members Nessan Bermingham, Ph.D., Jean-François Formela, M.D., Shinichiro Fuse, Ph.D., Douglas Kerr, M.D., Ph.D., MBA, and Nikola Trbovic, Ph.D.
During her 15-year tenure at Alkermes, Biberstein was responsible for a wide range of functions across legal, intellectual property, government affairs, policy and operations.

As general counsel, she established the legal function and held operational and strategic roles in major licensing and mergers and acquisitions transactions.

She was instrumental in the company's nearly USD1 bn merger with Elan Drug Technologies.

Biberstein currently serves as an observer on the Investment Committees of the UBS Oncology Impact Fund and Oncology Impact Fund 2 and on the Biopharma Advisory Team of FocusMaine.

She received her B.S. in mechanical-electrical engineering from Kettering University and her J.D. from the University of Michigan Law School.

During his tenure at Spark Therapeutics, Webster served as the chief financial officer, notably leading its IPO in 2015. Prior to joining Spark, he was senior vice president, finance, and chief financial officer at Optimer Pharmaceuticals and Adolor Corp., both of which were acquired by Cubist Pharmaceuticals.

He held the role of president and CEO at Neuronyx, of which he was a co-founder. Webster also has experience in investment banking, previously serving as managing director at Broadpoint Capital and director at PaineWebber (now UBS). He received his A.B. in economics from Dartmouth College and his MBA from The Wharton School of the University of Pennsylvania.

Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders a group of more than 50 known genetic diseases including myotonic dystrophy type 1, Huntington's disease, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis leveraging insights from patient genetics.

Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the company to develop a single oligonucleotide targeting the DNA Damage Response pathway to potentially treat multiple REDs.

Triplet is headquartered in Cambridge, Mass.